Another attractive target for cancer immunotherapy is B7-H3 (CD276); this molecule plays a key role in the inhibition of T-cell function [34,200,201,202,203,204] and it is highly expressed on a wide range of human solid cancers; Its expression often correlates with both negative prognosis and poor clinical outcome of patients [202,203]. This evidence concerns the gene CD276 and cancer.